spacer
home > epc > spring 2002 > global parallel trade - a growing concern
PUBLICATIONS
European Pharmaceutical Contractor

Global Parallel Trade - A Growing Concern

In an industry traditionally confined to Europe, evidence suggests that parallel trade is now expanding globally. This relatively young, yet highly controversial industry sector is breaking free from the confines of the EU and is taking a foothold in non-EU countries such as Russia, South Africa, India, and the Philippines, according to a new report published by Reuters Business Insight. Within the EU, parallel trade is also shown to be expanding as a result of increased numbers of parallel import licences granted, EU enlargement, national cost-containment drives on drug spending, and litigation victories for parallel traders - activities that are forecast to drive the parallel trade market to a US$7.4 billion industry by 2006. In The Global Parallel Trade Outlook, 2001-2006, new trends in parallel trade are identified along with potential new market opportunities that the industry has created under the current political, legal and regulatory framework of 27 countries. The report's author provides a short commentary on how parallel trade is expanding and what this could mean for the global pharmaceutical industry.

In the EU, parallel trade or parallel distribution has been a legitimate industry since the 1970s, when drugs were bought from low-priced countries and sold in high-priced countries despite the availability and distribution of locally manufactured equivalents in the import and export countries. There are a number of advantages and disadvantages to parallel trade. The most obvious and important is the financial reward from selling cheaply purchased drugs to higher priced economies. In addition, parallel trade stimulates competition and benefits the health care provider and patient through lower drug prices. The downside, however, includes the loss of revenue for the manufacturer, erosion of domestic sales, and not least is the point that parallel trade is a highly litigious practice costing firms millions of dollars each year.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tim Atkinson, Independent Biopharmaceutical Analyst

Tim Atkinson BSc (Hons), a former Biomedical Scientist and Medical Editor and Writer, has worked for over 10 years in scientific and medical publishing environments. He has written on a number of industry-related topics ranging from pharmaceutical e-commerce to drug delivery and biomaterials. He is currently working as an independent Biopharmaceutical Analyst on assignments for companies such as Reuters Business Insight and IMS Health where he has produced in-depth market intelligence business and health care reports aimed at senior executives in the pharmaceutical industry. With over 15 publications to date, Tim is currently researching and writing on lifestyle drugs and innovation in R&D.

spacer
Tim Atkinson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

ECCRT

ECCRT

The European Centre for Clinical Research Training (ECCRT) is a professional clinical research training provider focusing on the transfer of implementable knowledge for the day-to-day activities of our participants whether being new to the industry, starters on the job, or seasoned professionals. Our mission is to facilitate Clinical Research professionals to excel in their job for the benefit of patients. We aim to achieve this by providing clinical research professionals with competencies to develop new therapies for patients quicker & more efficiently, without jeopardizing quality and safety.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement